Ghrelin Receptor Peptides in Canada: A Research Guide to GHSR Signalling, GH Pulsatility, Ipamorelin, GHRP-6, and RUO Controls

Why ghrelin receptor peptides deserve a dedicated growth-hormone guide#

Northern Compound already covers GH pulsatility peptide research, somatostatin tone and GH peptides, IGF-1 feedback, compound-level guides for Ipamorelin, GHRP-6, Sermorelin, and CJC-1295 without DAC, plus broader buyer-intent resources such as best growth-hormone peptides in Canada. What was still missing was a receptor-first guide: how should Canadian readers evaluate research claims when the central mechanism is the ghrelin receptor, also called the growth hormone secretagogue receptor or GHSR?

That gap matters because “GH secretagogue” is often used as a loose marketing category. Some materials act through the ghrelin receptor. Some act through the GHRH receptor. Some are recombinant hormone rather than secretagogue material. Some older compounds discussed in forums or review papers are not live products on the current Lynx Labs map and should not be treated as available store destinations. A receptor-level guide prevents those categories from being blurred.

Ghrelin receptor signalling sits at an endocrine crossroads. It can influence growth hormone release, appetite, gastric motility, glucose handling, reward circuitry, stress biology, sleep-state variables, and autonomic tone depending on model, tissue, ligand, timing, and endpoint. The same receptor family can therefore appear in growth-hormone research, metabolic research, gut-brain research, and neuroendocrine research. That breadth is useful scientifically, but it raises the risk of unsupported claims.

This article is written for non-clinical, research-use-only evaluation in Canada. It does not provide medical advice, hormone treatment guidance, body-composition guidance, dosing, injection technique, cycle design, reconstitution instruction, compounding advice, or personal-use recommendations. Disease, endocrine, and metabolic terms appear because they are used in experimental literature and supplier evaluation, not because RUO materials have therapeutic indications.

The short answer: GHSR questions need endocrine-axis controls#

A credible ghrelin receptor peptide project starts by naming the layer under test. Is the hypothesis receptor pharmacology, pituitary GH release, hypothalamic interaction with GHRH and somatostatin, appetite signalling, glucose context, or a practical supplier-quality question? Those are related, but they are not the same study.

Within the current live product map, Ipamorelin is the most focused ghrelin-receptor reference for protocols that want to examine GH secretagogue signalling with a comparatively narrow endocrine profile. GHRP-6 is relevant when the model intentionally includes older GHRP literature, appetite or orexigenic signalling, and broader ghrelin-like physiology. CJC-1295 without DAC and Sermorelin are not ghrelin receptor ligands; they belong when the study needs GHRH-axis comparators, pulse-context controls, or combination logic. CJC-1295 with DAC can be relevant to longer-acting GHRH analogue questions, but it should not be described as GHSR activation.

Some well-known names in the broader category, including GHRP-2, hexarelin, MK-677, and several older secretagogue research compounds, are important in the literature but are not appropriate live product links when they are not confirmed available. When a material is not live, a cautious article can discuss it as context without creating a product link that may send readers to a 404.

Ghrelin and GHSR biology in one careful map#

Ghrelin is a stomach-derived peptide hormone best known for its acylated active form and its role in growth hormone release and appetite signalling. The growth hormone secretagogue receptor, often abbreviated GHSR or GHS-R1a, is a G-protein-coupled receptor expressed in pituitary, hypothalamic, and other tissues. Ghrelin was identified after synthetic growth hormone secretagogues had already shown that a receptor existed, which is why the nomenclature can feel backwards: the receptor was named for secretagogues before the endogenous ligand became central to the story.

Ghrelin can stimulate GH secretion through pituitary action and through hypothalamic integration with GHRH and somatostatin. Reviews describe ghrelin as a growth hormone-releasing factor and emphasize that its effects are not isolated from the rest of the neuroendocrine axis (PMID: 23652391; PMID: 20616513). The receptor also appears in discussions of appetite, gastrointestinal motility, glucose metabolism, reward, stress, and sleep. That broader physiology is why GHSR research should not measure GH alone when the hypothesis involves behaviour, metabolism, or recovery state.

The active ghrelin story depends on acylation. Acyl-ghrelin can bind and activate GHSR; des-acyl ghrelin has different biology and cannot simply be treated as inactive background. Enzymes that modify ghrelin, feeding state, fasting, glucose, insulin, circadian timing, and stress can all change the baseline endocrine environment. A peptide experiment that ignores feeding state or sampling time may see variability that has nothing to do with the supplied material.

GHSR also shows constitutive activity and complex signalling. Depending on ligand and model, researchers may measure phospholipase C pathways, intracellular calcium, ERK, beta-arrestin recruitment, receptor internalisation, or downstream endocrine output. A clean pharmacology paper and a whole-animal endocrine paper answer different questions. The former can ask whether a ligand activates a receptor. The latter asks how a living axis integrates that signal.

Ipamorelin: the focused GHSR reference, not a complete axis by itself#

Ipamorelin is usually discussed as a selective growth hormone secretagogue with ghrelin-receptor agonist activity. In practical editorial terms, it is the cleanest live product reference when the research question is: what happens when a GHSR-directed peptide is used to probe GH release with less emphasis on broad cortisol or prolactin movement than older secretagogues?

That phrasing should remain careful. “Selective” does not mean context-free. A model can still be shaped by sex, age, strain, pituitary reserve, sleep state, feeding state, glucose, stress, endogenous ghrelin, GHRH tone, somatostatin tone, and receptor desensitisation. An Ipamorelin study that measures one GH time point may show a signal, but it does not fully describe pulse architecture or downstream IGF-axis interpretation.

A strong Ipamorelin protocol would measure multiple time points around expected pulse timing; include baseline and vehicle arms; consider GHRH-axis comparators when the question is synergy; and track IGF-1, IGFBP-3, glucose, insulin, and stress markers where the model makes those variables relevant. If the outcome is behavioural or body-composition-adjacent in an animal model, the protocol should add food intake, locomotion, body weight, hydration, and circadian controls before attributing the result to GH alone.

For Canadian RUO sourcing, Ipamorelin should be evaluated for lot-specific HPLC purity, identity confirmation, fill amount, batch number, storage guidance, and clear research-use-only labelling. The supplier page is a documentation starting point. It is not evidence of a human endocrine outcome, and it does not replace batch-level review.

GHRP-6: older secretagogue literature and appetite-aware design#

GHRP-6 is an older growth hormone releasing peptide that remains important in secretagogue research. It is often discussed around GH release, ghrelin-like signalling, appetite effects, and the historical development of GHSR pharmacology. In a receptor-first guide, GHRP-6 is useful when the protocol intentionally wants a broader GHSR-associated signal rather than the narrowest possible endocrine readout.

The appetite context is not a side note. Ghrelin receptor activation can influence feeding and gut-brain signalling. If a study uses an animal model and measures body weight, lean mass, recovery, sleep, activity, or metabolism, food intake and feeding schedule can become major confounders. A change in downstream tissue state may reflect altered caloric intake, stress, locomotion, or glucose handling rather than a direct GH-mediated tissue effect.

A careful GHRP-6 study should therefore pair GH endpoints with appetite and metabolic controls when appropriate. Useful readouts include food intake, meal timing, gastric emptying or motility markers where relevant, glucose, insulin, GH pulses, IGF-1 context, and stress hormones if the literature suggests a broader endocrine profile. If the research question is purely pituitary GH release, then appetite variables can be kept outside the model. If the outcome is metabolic or behavioural, they cannot be ignored.

GHRP-6 should also be treated as a specific chemical identity, not a generic label for every GHRP. GHRP-2, hexarelin, Ipamorelin, and non-peptide secretagogues can differ in potency, selectivity, endocrine side signals, and pharmacokinetics. A review statement about “growth hormone secretagogues” should not be copied into a product-specific claim unless the cited material actually matches the supplied compound.

GHRH-side comparators: CJC-1295 and Sermorelin are not ghrelin receptor ligands#

GHRH analogues are often discussed beside ghrelin receptor peptides because both categories can increase GH output in model systems. Mechanistically, however, they occupy different lanes. Sermorelin corresponds to the active portion of growth hormone releasing hormone and is used in research to probe the GHRH receptor side of the axis. CJC-1295 without DAC is a modified GHRH analogue often discussed around shorter-acting pulse support in research contexts. CJC-1295 with DAC incorporates a drug affinity complex and belongs to longer-exposure GHRH analogue questions.

None of those materials should be described as ghrelin receptor peptides. They are relevant because GH secretion is controlled by interacting signals. Ghrelin receptor activation can be more or less effective depending on GHRH availability, somatostatin tone, pituitary state, and sampling time. Conversely, a GHRH analogue can look different when paired with a GHSR ligand than when studied alone.

Combination logic is scientifically interesting but interpretively harder. A study that uses a GHRH analogue and a GHSR ligand together should include single-agent arms, combination arms, vehicle controls, and a time-course dense enough to see whether peak height, pulse frequency, duration, or nadir recovery changed. Without those arms, the result becomes a black box. It may show increased GH output, but it cannot assign the effect to GHRH signalling, GHSR signalling, pituitary reserve, or altered somatostatin restraint.

This distinction is also important for supplier content. A product page for CJC-1295 without DAC or Sermorelin can be useful for GHRH-axis documentation. It should not be used to imply ghrelin receptor engagement.

GH pulsatility: one blood draw is not an endocrine profile#

Growth hormone is secreted in pulses. That fact makes endpoint design difficult. A single measurement can miss the peak, catch a nadir, or overstate a transient event. Northern Compound’s GH pulsatility guide covers this in detail, but ghrelin receptor research needs the lesson even more because secretagogue effects are often acute and timing-sensitive.

A strong pulse study asks several questions. Did the peptide increase peak amplitude? Did it change pulse frequency? Did it shorten or lengthen pulse duration? Did the nadir recover? Did it alter the next spontaneous pulse? Did it change IGF-1 later, or only GH acutely? Did the response vary with feeding state, sleep phase, age, sex, or baseline endocrine reserve? Each question requires different sampling.

Area under the curve can be useful, but it can hide pulse shape. A broad, modest elevation and a sharp, brief peak may produce similar total exposure while implying different biology. IGF-1 can help connect acute GH to downstream hepatic signalling, but IGF-1 itself has timing, binding-protein, nutrition, and tissue-context limitations. IGFBP-3 and acid-labile subunit context may matter when the question is sustained axis output rather than a brief pituitary response.

For ghrelin receptor peptides, pulse discipline also protects against overreading negative studies. A material may appear inactive if sampled at the wrong time, in the wrong feeding state, or after receptor desensitisation. The answer is not to assume efficacy; it is to design the sampling plan around the biology.

Somatostatin tone and pituitary reserve: two hidden variables#

Somatostatin restrains GH release. GHRH stimulates it. Ghrelin receptor activation interacts with both. That means a ghrelin receptor peptide may produce different results depending on whether somatostatin tone is high or low at the time of exposure. The same dose in the same model can produce a different GH profile if sampling occurs during a natural pulse, during a suppressed state, after stress, or after feeding.

Pituitary reserve is another hidden variable. A pituitary that can release GH robustly will not respond like a pituitary that is developmentally immature, aged, stressed, inflamed, or otherwise constrained. A study in healthy young animals cannot be imported into an aged or disease model without checking reserve. A cell-line receptor assay cannot be imported into whole-axis physiology without hypothalamic and pituitary context.

Researchers can manage these issues with comparator arms. A GHRH-side material such as Sermorelin can help probe whether pituitary responsiveness is intact. A ghrelin receptor material such as Ipamorelin can help probe GHSR-mediated output. Together, with proper controls, they can map axis responsiveness. Without controls, they simply create a larger endocrine perturbation that is harder to interpret.

Non-GH signals: appetite, glucose, cortisol, prolactin, and behaviour#

GHSR biology reaches beyond GH. Reviews of growth hormone secretagogues describe endocrine and non-endocrine actions, including GH release and other neuroendocrine effects depending on ligand and model (PMID: 11322506; PMID: 12435899). Ghrelin reviews likewise discuss pituitary and broader regulatory roles (PMID: 20616513).

This broader biology does not make every GHSR peptide a metabolic, cognitive, or recovery compound. It means the endpoint panel must protect against confounding. If a model measures weight, activity, lean mass, tissue repair, or behaviour, appetite and locomotion need attention. If a model measures glucose or insulin, feeding state and sampling time matter. If a study uses older secretagogues or a broad endocrine ligand, cortisol and prolactin can be relevant. If sleep or stress state changes, GH interpretation becomes more complicated.

Ipamorelin is often chosen when a narrower endocrine profile is desired, while GHRP-6 may be chosen when older GHRP and appetite-linked biology are part of the question. But selectivity is always relative. The correct editorial move is not to rank compounds by hype. It is to match the material to the endpoint and then measure the likely confounders.

Receptor desensitisation, timing, and repeated exposure#

G-protein-coupled receptors can desensitise, internalise, recycle, or shift signalling bias with repeated stimulation. GHSR is no exception. A study that uses repeated exposure should ask whether the response is stable, diminished, or altered over time. Acute GH release after one exposure does not prove sustained axis behaviour after repeated pulses.

Desensitisation matters for interpretation. A declining GH response may reflect receptor adaptation, pituitary depletion, increased somatostatin tone, altered feedback, feeding-state change, stress, or material instability. A sustained response may reflect preserved receptor sensitivity, changed baseline physiology, or simply sampling at favourable times. Time-course design and controls are required.

For RUO materials, repeated-exposure studies also depend on storage handling. A peptide that degrades during a long protocol can mimic receptor desensitisation. A concentration error can mimic tachyphylaxis or sensitisation. The storage log, aliquot strategy, freeze-thaw record, and assay matrix are part of the experiment even when the article does not provide practical handling instructions.

Endpoint panel for a credible GHSR peptide study#

A minimal endpoint panel depends on the research question, but a serious ghrelin receptor project usually needs more than one GH value.

Positive and negative controls help. A GHRH analogue can test a different arm of the axis. A vehicle arm is mandatory. A receptor-antagonist or pathway-control arm may be useful in cell systems. In vivo endocrine studies should pre-specify sampling windows and avoid opportunistic measurements that can be fitted to a narrative after the fact.

Supplier and COA review for Canadian RUO GHSR research#

Ghrelin receptor studies are sensitive to identity and concentration. A small fill error can change a pulse-response curve. Degradation can reduce activity. Incorrect sequence, salt form, or peptide content can make a selective ligand look weak or messy. Residual solvents, endotoxin, pH, salts, or microbial contamination can alter stress and endocrine endpoints. These issues are not administrative details; they can become biological artefacts.

Before interpreting a GHSR peptide experiment, Canadian readers should look for:

• lot-specific HPLC purity rather than a generic purity statement;
• mass confirmation or another identity method appropriate to the peptide;
• exact peptide name, sequence or analogue description, fill amount, batch number, and vial label matching the COA;
• research-use-only labelling with no treatment, dosing, bodybuilding, anti-ageing, or personal-use promises;
• storage and shipping expectations that match peptide sensitivity;
• documentation of assay matrix, aliquoting, freeze-thaw exposure, and timing in the laboratory record;
• caution around unavailable products: do not treat dead or unverified product slugs as live store destinations.

Product pages for Ipamorelin, GHRP-6, CJC-1295 without DAC, Sermorelin, and CJC-1295 with DAC are starting points for documentation review. They are not medical recommendations and they do not replace batch-level verification.

How to read ghrelin receptor claims without overstating them#

A practical editorial review can use six questions.

First, is the compound actually a ghrelin receptor ligand? Ipamorelin and GHRP-6 belong in GHSR discussion. Sermorelin and CJC-1295 belong to GHRH analogue discussion. Recombinant HGH is hormone replacement material in research context, not a secretagogue. Mixing those categories creates confusion.

Second, was GH measured as a pulse or as a single value? Pulse architecture matters. A single peak does not describe frequency, duration, nadir, or downstream feedback.

Third, what was the model state? Feeding, sleep, age, sex, stress, glucose, pituitary reserve, endogenous ghrelin, GHRH, and somatostatin all shape response.

Fourth, were non-GH signals measured? Appetite, gastric motility, glucose, insulin, cortisol, prolactin, activity, and stress can explain outcomes that might otherwise be credited to GH.

Fifth, did downstream markers support the claim? IGF-1, binding proteins, tissue-specific GH receptor markers, and functional endpoints should match the claim. Acute GH release alone should not be converted into broad claims about recovery, body composition, ageing, or cognition.

Sixth, was the material verified? Without COA confidence, sequence identity, fill accuracy, and storage discipline, subtle endocrine differences are not interpretable.

Evidence snapshots and cautious reference points#

The ghrelin receptor and growth hormone secretagogue literature is large. This article is not a systematic review; it is a framework for reading claims.

Ghrelin is described in endocrine reviews as a GH-releasing factor that interacts with pituitary and hypothalamic regulation rather than acting as an isolated GH switch (PMID: 23652391; PMID: 20616513). That supports a receptor-axis framework, not product-level efficacy claims.

Reviews of growth hormone secretagogues discuss biological activities beyond GH and the clinical-relevance questions that made older GHS research complex (PMID: 11322506; PMID: 12435899). For RUO editorial purposes, the takeaway is endpoint caution: secretagogues can move more than one signal.

Recent review indexing continues to place hypothalamic GHRH and GH regulation inside a broader endocrine network rather than a simple on/off model (PMID: 39913072). That matters when researchers compare ghrelin receptor materials with GHRH analogues such as Sermorelin or CJC-1295 without DAC.

The responsible claim is narrow: ghrelin receptor peptides can be useful research tools for probing GHSR-mediated GH release and related endocrine physiology when the study measures pulse timing, axis context, confounders, and material quality. They are not generic instructions for changing human hormone profiles.

Internal linking map for related Northern Compound research#

Readers evaluating GHSR claims should usually move through several related guides:

• Use GH pulsatility peptide research when the main question is pulse shape, sampling density, amplitude, frequency, or nadir recovery.
• Use somatostatin tone and GH peptides when the claim involves restrained GH release, rebound, or axis timing.
• Use IGF-1 feedback peptide research when acute GH signals are being converted into downstream liver or tissue claims.
• Use the Ipamorelin guide for compound-specific GHSR context.
• Use the GHRP-6 guide when older GHRP literature, appetite, or ghrelin-like signalling is central.
• Use the CJC-1295 without DAC guide, CJC-1295 DAC vs no DAC comparison, and Sermorelin guide when the question is GHRH-axis comparison rather than ghrelin receptor activation.
• Use best growth-hormone peptides in Canada for broad buyer-intent orientation before narrowing to receptor-level questions.

This map prevents category drift. GHSR, GHRH, recombinant GH, IGF-axis signalling, appetite biology, and recovery claims overlap, but they are not interchangeable.

Practical red flags in GHSR product and article claims#

Be cautious when an article says a peptide “boosts GH” without explaining pulse timing. Be more cautious when it jumps from GH release to body-composition, recovery, sleep, anti-ageing, or cognition claims without downstream endpoints. Be especially cautious when it uses human treatment language for an RUO product.

Other red flags include missing COAs, generic purity claims, no mass confirmation, no batch number, unclear fill amount, dead product links, unsupported route language, personal-use wording, and claims that collapse Ipamorelin, GHRP-6, CJC-1295, Sermorelin, and HGH into one category. These materials answer different questions.

A better supplier-facing claim is modest: “This RUO material may be relevant to non-clinical research on ghrelin receptor or growth-hormone-axis signalling when paired with appropriate endocrine endpoints and batch-level documentation.” That language is less dramatic, but it is more scientifically defensible.

Canadian protocol design: choosing the right comparison frame#

A useful ghrelin receptor protocol begins before the peptide is chosen. It begins with the comparison frame. If the question is receptor pharmacology, the appropriate comparator may be another GHSR ligand, a pathway inhibitor, or a receptor-negative model. If the question is growth-hormone-axis output, the comparator may be a GHRH-side material such as Sermorelin, a shorter-exposure GHRH analogue such as CJC-1295 without DAC, or a vehicle arm designed around dense sampling. If the question is downstream tissue signalling, the protocol must decide whether the acute pulse, repeated exposure, or IGF-axis response is the primary event.

This distinction matters because a study can be internally valid and still answer the wrong question. A cell-based GHSR activation assay can rank ligands for receptor engagement, but it cannot prove GH pulsatility. A pituitary-cell assay can show secretory capacity, but it cannot describe hypothalamic somatostatin restraint. A whole-animal endocrine study can show integrated physiology, but it may be confounded by feeding, sleep, stress, and locomotion unless those variables are measured. A supplier article that treats all of those designs as identical is not reading the evidence carefully.

Canadian readers should also watch for category substitution. A post may start with Ipamorelin, cite a broad ghrelin review, mention MK-677 or hexarelin literature, and then imply that all secretagogues behave the same way. That is not strong enough. Each material has its own receptor pharmacology, exposure profile, and endocrine side-signal history. If a compound is not confirmed as a live product, it should remain literature context rather than a product destination. If a compound is live, the product page still needs batch-level verification before any research interpretation is made.

For non-clinical research planning, the cleanest structure is often a matrix:

• a vehicle control to define baseline pulse variability;
• a GHSR-focused arm such as Ipamorelin when receptor-mediated secretagogue output is the core question;
• a broader older-GHRP arm such as GHRP-6 when appetite or historical secretagogue literature is relevant;
• a GHRH-side comparator such as Sermorelin when pituitary responsiveness must be separated from GHSR signalling;
• optional combination arms only if the study can support attribution with single-agent arms;
• pre-specified endocrine, metabolic, and behavioural endpoints that match the claim.

This does not make the protocol simple. It makes the interpretation less fragile. The point of receptor-aware design is not to produce the largest possible GH signal; it is to identify which part of the axis moved and whether the supplied material was interpretable.

Common wording problems in growth-hormone secretagogue content#

The first wording problem is the phrase “natural GH release” used as if it solves all interpretive issues. Secretagogue models may depend on endogenous pituitary reserve and hypothalamic context, but that does not make the result automatically physiological, beneficial, or safe. RUO content should not use “natural” as a substitute for endpoint data.

The second problem is collapsing pulse amplitude into overall axis improvement. A larger peak can be experimentally interesting while saying little about frequency, duration, downstream IGF signalling, receptor adaptation, or tissue response. If the article does not discuss time-course design, it is probably overconfident.

The third problem is ignoring appetite. Ghrelin receptor biology is tightly linked to feeding signals. In animal models, altered intake can change body weight, glucose, insulin, activity, recovery, and tissue state. If a study reports downstream outcomes but does not control food intake or feeding schedule, the GH explanation should be treated as incomplete.

The fourth problem is using dead or unavailable product destinations. The broader internet may discuss GHRP-2, hexarelin, MK-677, and other secretagogues as if they are interchangeable buying options. Northern Compound should be stricter. If a slug is confirmed dead on Lynx Labs, do not use it in the ProductLink component. If the material is relevant to the literature, name it as context and explain the limitation.

The fifth problem is route and dosing language. Growth-hormone-axis content attracts personal-use interpretation quickly. A compliant Canadian research article should avoid instructions, cycles, stacking advice, and outcome promises. It can discuss sampling density, COA review, receptor specificity, and model selection without telling a reader how to use a material.

A better editorial standard is plain: describe the receptor, name the endpoint, separate GHSR from GHRH, disclose RUO status, link only to live documented products through ProductLink, and keep the claim no broader than the data.

A sample evidence grading ladder for GHSR claims#

Not every claim deserves the same confidence. A simple grading ladder can help readers sort the literature and supplier language.

Low-confidence claims rely on category labels. “Ghrelin peptide,” “GH booster,” “secretagogue,” or “supports recovery” are not mechanisms. They tell the reader what market category the material sits in, not what the experiment measured.

Moderate-confidence claims cite a relevant study but import too much from it. For example, a paper may show acute GH release after a specific ligand in a controlled model. That supports acute endocrine activity in that model. It does not prove repeated exposure, downstream IGF-axis change, tissue repair, fat loss, sleep improvement, or anti-ageing effects.

Higher-confidence claims match compound, model, timing, and endpoint. A stronger statement would say that a defined GHSR ligand changed GH pulse amplitude over a defined sampling window in a specified animal or cell model, with vehicle controls and relevant endocrine markers. That still does not become human guidance, but it is scientifically clearer.

The strongest supplier-adjacent claim adds material verification. If the experiment used a lot with HPLC purity, identity confirmation, documented fill, storage records, and RUO labelling, the biological result becomes more interpretable. If the product page lacks those details, confidence should drop even if the mechanism sounds plausible.

Where this guide fits in the archive#

This article fills a growth-hormone archive gap between compound-level guides and axis-level guides. Compound guides answer “what is this material in the literature?” Axis guides answer “how should a mechanism be measured?” A ghrelin receptor guide does both: it explains why Ipamorelin and GHRP-6 belong together mechanistically, why Sermorelin and CJC-1295 without DAC belong nearby but not inside the same receptor class, and why HGH is a separate reference point.

For readers arriving from search, the practical takeaway is not “choose a secretagogue.” It is: decide whether the question is receptor activation, GH pulse biology, GHRH comparison, somatostatin restraint, IGF feedback, appetite confounding, or supplier documentation. Then read the relevant article and inspect current COAs accordingly.

FAQ#

Bottom line#

Ghrelin receptor peptides deserve a dedicated category inside growth-hormone research because they answer a specific axis question: how does GHSR-mediated secretagogue signalling interact with GH pulses, GHRH tone, somatostatin restraint, downstream IGF feedback, appetite, glucose, stress, and supplier quality?

The strongest Canadian RUO interpretation is receptor-specific and endpoint-specific. Ipamorelin is the clearest live reference for narrower GHSR-oriented GH secretagogue research. GHRP-6 is useful when older GHRP and appetite-aware design are central. Sermorelin, CJC-1295 without DAC, and CJC-1295 with DAC belong on the GHRH-comparator side, not inside the ghrelin receptor mechanism itself. HGH is a different category again.

For readers comparing suppliers, the practical rule is simple: mechanism claims need mechanism endpoints, endocrine claims need pulse-aware sampling, and product claims need lot-specific documentation. Anything broader should be treated as marketing until the evidence catches up.